Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
明尼阿波利斯，2024年5月8日（环球新闻专线）——致力于开发肿瘤靶向疗法的临床阶段生物技术公司Celcuity Inc.（纳斯达克股票代码：CELC）今天宣布，将在2024年5月15日星期三收盘后发布2024年第一季度的财务业绩。管理层将在美国东部时间当天下午 4:30 主持网络直播/电话会议，讨论结果并提供公司最新情况。
Webcast and Conference Call Information
网络直播和电话会议信息
To participate in the teleconference, domestic callers should dial 1-888-886-7786 and international callers should dial 1-416-764-8658. A live webcast presentation can also be accessed using this weblink: A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
要参加电话会议，国内来电者应拨打 1-888-886-7786，国际来电者应拨打 1-416-764-8658。也可以使用此网络链接访问网络直播演示：直播结束后，将在Celcuity网站上重播网络直播。
关于 Celcuity
Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is enrolling patients. The company's CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Further information about Celcuity can be found at . Follow us on LinkedIn and Twitter.
Celcuity是一家临床阶段的生物技术公司，专注于开发治疗多种实体瘤适应症的靶向疗法。该公司的主要候选治疗药物是gedatolisib，这是一种有效的泛PI3K和mTOR抑制剂。其作用机制和药代动力学特性与目前其他已批准和正在研究的单独或同时靶向PI3K或mTOR的疗法有很大区别。一项名为 VIKTORIA-1 的3期临床试验目前正在招收患者，该试验评估了格达托利西布与氟维司朗联合使用或不含palbociclib对HR+/HER2-晚期乳腺癌患者进行治疗。有关 VIKTORIA-1 研究的更多详细信息可以在ClinicalTrials.gov上找到。一项名为 CELC-G-201 的 1b/2 期临床试验，正在招收患者，该试验评估了吉达托利西布与达洛他胺联合治疗转移性去势抗性前列腺癌患者。该公司的CelSignia伴随诊断平台具有独特的能力，能够分析活体患者肿瘤细胞，以识别可能受益于已批准的靶向疗法的新癌症患者群体。有关 Celcuity 的更多信息，请访问。在领英和推特上关注我们。
View source version of release on GlobeNewswire.com
在 GlobeNewswire.com 上查看版本的源版本
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
联系人：
Celcuity Inc.
布莱恩·沙利文，bsullivan@celcuity.com
Vicky Hahne，vhahne@celcuity.com
(763) 392-0123
ICR Westwicke
Maria Yonkoski, maria.yonkoski@westwicke.com
(203) 682-7167
ICR Westwicke
玛丽亚·扬科斯基，maria.yonkoski@westwicke.com
(203) 682-7167